Tag: Breast Cancer
1. The study found no evidence of benefit to disease-free survival when 400 mg of celecoxib was administered once daily for 2 years in patients with ERBB2-negative breast cancer as compared to the placebo group.
2. Due to gastrointestinal and cardiac adverse effects related to COX-2 inhibition, longer-term treatment or...
1. Tamoxifen reduced the long-term risk of breast cancer metastasis or recurrence and improved survival, especially in large, low-grade progesterone receptor-positive, or Ki-67-positive patients, compared to no tamoxifen treatment.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Breast cancer is the most common cancer for women. Estrogen-receptor (ER)-positive breast cancer treatment currently...
1. The incidence of fibroadenoma, epithelial proliferation with and without atypia, and fibrocystic changes peak in women in their 40s, while cysts peak at 50.
2. Hormone-altering activities impact risk for benign breast diseases, including regular menstruation, parity, younger age of first birth, breastfeeding, oral hormonal contraceptives; obesity specifically reduces...
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to single-agent chemotherapy treatment.
2. Sacituzumab govitecan was associated with more frequent events of myelosuppression and diarrhea compared to chemotherapy treatment.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Breast cancer patients with triple-negative status...
1. Heterogeneity in histological profile linked to improved overall survival, chemotherapy response, and clinical course despite triple-negative receptor status in three rare breast cancer histological subtypes.
2. Metaplastic breast carcinoma had the worst 5-year overall survival (OS) among the subtypes studied and factors associated with its poor prognosis included advanced...
Click to read the study in Clinical Cancer Research.
Click to read the study in JAMA Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in the European Journal of Cancer.
Click to read the study in the Journal of Clinical Oncology.